Zobrazeno 1 - 10
of 254
pro vyhledávání: '"Thomas W. Klein"'
Publikováno v:
Pain Research and Management, Vol 6, Iss 2, Pp 95-101 (2001)
The effect of cannabimimetic agents on the function of immune cells such as T and B lymphocytes, natural killer cells and macrophages has been extensively studied over the past several decades using human and animal paradigms involving whole animal m
Externí odkaz:
https://doaj.org/article/86863c22cf62490f9096c6547e319204
Autor:
Yingquan Xiong, Shufei Zeng, Lianghong Yin, Chang Chu, Thomas W. Klein, Ahmed A. Hasan, Sandra Frankenreiter, Berthold Hocher, Bernhard K. Krämer, Denis Delic
Publikováno v:
Diabetes. 69
SGLT2 inhibition has beneficial effects on cardiovascular and renal endpoints but the lowest effective dose is unknown. Effects of the SGLT2 inhibitor, empagliflozin (EMPA) were evaluated in nondiabetic, 5/6 nephrectomy (5/6 Nx) rats. Rats were treat
Publikováno v:
Diabetes. 69
Despite a similar mechanism of action underlying their glucose-lowering effects, dipeptidyl peptidase-4 (DPP-4) inhibitors have diverse molecular structures, raising the prospect of agent-specific, glucose-independent actions. This possibility is sup
Autor:
Sergi Sayols, Holger Klein, Michael Mark, Thomas W. Klein, Gerd Luippold, German Leparc, Eric Simon
Publikováno v:
Diabetes. 68
Recent data suggest that the individual microbiome influences the pathology of type 2 diabetes (T2D). Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor used for the treatment of T2D, which is excreted mainly via the bile. We investigated the
Psychoneuroimmunology is the emerging science devoted to studying the two-way relationship between the nervous and immune systems. Psychoneuroimmunology, Stress, and Infection highlights the latest information concerning microbial infections in both
Autor:
Thomas W. Klein, Florian Kahles, Michael Lehrke, Julia Moellmann, Michael Mark, Elias Haj-Yehia, Nikolaus Marx, S. Diebold
Publikováno v:
Diabetes. 67
DPP-4 inhibitors are a class of antidiabetic drugs which act by augmentation of the GLP-1 system and insulin secretion. Despite similar glucose lowering efficacy within the class, only saxagliptin increased heart failure hospitalization in diabetic p
Autor:
Fausto Chiazza, Hiranya Pintana, Massimo Collino, Cesare Patrone, Thomas Nyström, Vladimer Darsalia, Grazyna Lietzau, Harald Tammen, Thomas W. Klein
Publikováno v:
Diabetes. 67
Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) decrease hyperglycemia by inhibiting glucagon-like peptide-1 (GLP-1) cleavage. Gliptins can also improve stroke outcome in rodents independently of GLP-1R. However, the underlying mechanisms are un
Publikováno v:
Diabetes. 67
We recently reported that linagliptin (LINA) and empagliflozin (EMPA) monotherapies exhibit favorable effects in the heart, vasculature and kidneys in murine models of prediabetes and diabetes. Herein, we extend those studies by testing whether these
Publikováno v:
Diabetes. 67
Nonalcoholic steatohepatitis (NASH) and diabetes are common conditions that coexist and drive adverse outcomes. Empagliflozin (empa), a sodium-glucose co-transporter-2 inhibitor (SGLT2i), has achieved a 38% reduction in the cardiovascular (CV) and al